AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7041665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg per day for 3 consecutive days
Number of subjects: 392
Study 7041665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 200 mg in children
Number of subjects: 392
Study 7041665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 31788029 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous skin cell suspension (ReCell®)
Number of subjects: 150
Study 31788029 — intervention group
Group type: COMPARATOR
Intervention: Standard care interventions
Number of subjects: 150
Study 29912135 — intervention group
Group type: EXPERIMENTAL
Intervention: HALC
Number of subjects: 46
Study 29912135 — intervention group
Group type: COMPARATOR
Intervention: LAC
Number of subjects: 46
Study 26899484 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with ropivacaine and epinephrine
Number of subjects: 150
Study 26899484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infiltration)
Number of subjects: 150
Study 25132247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg/kg followed by 0.2 μg/kg per h infusion)
Number of subjects: 80
Study 25132247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 25132247 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 80
Study 18263874 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 115
Study 18263874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 115
Study 15871360 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of brimonidine tartrate
Number of subjects: 0
Study 11316161 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Number of subjects: 154
Study 11316161 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Number of subjects: 154
Study 15374128 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin (2 mg per night)
Number of subjects: 21
Study 15374128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8193492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg/kg
Number of subjects: 20
Study 8193492 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 20 micrograms/kg plus suxamethonium 1.5 mg/kg
Number of subjects: 20
Study 3788946 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial tracing
Number of subjects: 0
Study 3788946 — intervention group
Group type: COMPARATOR
Intervention: Missing migrant effect
Number of subjects: 0
Study 11495176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression (CBT-D)
Number of subjects: 179
Study 11495176 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behavioral smoking cessation treatment (ST)
Number of subjects: 179
Study 31016270 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity AVG-first access placement
Number of subjects: 50
Study 31016270 — intervention group
Group type: COMPARATOR
Intervention: AVF-first access placement
Number of subjects: 50
Study 28634000 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500 U
Number of subjects: 243
Study 28634000 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1000 U
Number of subjects: 243
Study 28634000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 27461800 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene post
Number of subjects: 16
Study 27461800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass post
Number of subjects: 16
Study 27461800 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite post
Number of subjects: 16
Study 24458754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24
Study 24458754 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control (CON)
Number of subjects: 24
Study 24458754 — intervention group
Group type: COMPARATOR
Intervention: No-exercise protein supplementation (PROT)
Number of subjects: 24
Study 22692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐, protein‐, and ribose‐containing repletion drink (TEST; n = 15)
Number of subjects: 32
Study 22692117 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrates alone (CON; n = 17)
Number of subjects: 32
Study 20412090 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% arnica
Number of subjects: 100
Study 20412090 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% vitamin K cream
Number of subjects: 100
Study 20412090 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% vitamin K and 0.3% retinol
Number of subjects: 100
Study 20412090 — intervention group
Group type: COMPARATOR
Intervention: white petrolatum
Number of subjects: 100
Study 17272735 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram for 12 weeks
Number of subjects: 0
Study 17272735 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 16210859 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 20 mg daily for 4 weeks
Number of subjects: 45
Study 16210859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12014839 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 treatment in senescent rat hearts
Number of subjects: 3
Study 12014839 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 pre-incubation in human atrial tissue
Number of subjects: 3
Study 12014839 — intervention group
Group type: COMPARATOR
Intervention: Oral CoQ10 therapy for 2 weeks pre-operatively
Number of subjects: 3
Study 11512194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified smoking cessation program (inpatient program)
Number of subjects: 89
Study 11512194 — intervention group
Group type: COMPARATOR
Intervention: Outpatient smoking cessation program
Number of subjects: 89
Study 7726101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing protection devices (HPDs) - three insert HPDs and an earmuff under sound field condition
Number of subjects: 12
Study 7726101 — intervention group
Group type: EXPERIMENTAL
Intervention: Earmuff (used only in sound field condition)
Number of subjects: 12
Study 7726101 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 12
Study 2343729 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.0, 2.0, and 3.0 MAC in 70% nitrous oxide)
Number of subjects: 4
Study 2343729 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (1.0, 2.0, and 3.0 MAC in 70% nitrous oxide)
Number of subjects: 4
Study 7028921 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (5 mg twice daily)
Number of subjects: 0
Study 7028921 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 0
Study 7028921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30166260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program (3 times weekly for 3 months)
Number of subjects: 50
Study 30166260 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintaining routine activities)
Number of subjects: 50
Study 28235533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 90
Study 28235533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with fentanyl 2.5 μg/mL
Number of subjects: 90
Study 28235533 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.0625% with fentanyl 2.5 μg/mL
Number of subjects: 90
Study 25794237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Chewing (GC)
Number of subjects: 30
Study 24014447 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions (stimulus condition)
Number of subjects: 74
Study 23734436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep duration at night (ASDN) (>= 7 hrs)
Number of subjects: 332
Study 23734436 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate sleep duration at night (ISDN) (< 7 hrs)
Number of subjects: 332
Study 19751085 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyad condition (patient and SO received the intervention)
Number of subjects: 161
Study 19751085 — intervention group
Group type: EXPERIMENTAL
Intervention: Solo condition (patient received the intervention)
Number of subjects: 161
Study 19751085 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 161
Study 17295801 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergen-specific IgE/IgG4
Number of subjects: 97
Study 17295801 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white (DBPCFC +)
Number of subjects: 97
Study 17295801 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat (DBPCFC +)
Number of subjects: 97
Study 17295801 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC for milk
Number of subjects: 97
Study 17295801 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC for egg white
Number of subjects: 97
Study 17295801 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC for soybean
Number of subjects: 97
Study 17295801 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC for wheat
Number of subjects: 97
Study 15533804 — intervention group
Group type: EXPERIMENTAL
Intervention: 103Pd implantation with 90 Gy
Number of subjects: 161
Study 15533804 — intervention group
Group type: EXPERIMENTAL
Intervention: 103Pd implantation with 115 Gy
Number of subjects: 161
Study 15533804 — intervention group
Group type: COMPARATOR
Intervention: 44 Gy external beam radiation
Number of subjects: 161
Study 12120181 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and treat strategy for Helicobacter pylori
Number of subjects: 0
Study 12120181 — intervention group
Group type: EXPERIMENTAL
Intervention: Test and scope strategy for Helicobacter pylori
Number of subjects: 0
Study 12120181 — intervention group
Group type: COMPARATOR
Intervention: Eradication of H. pylori
Number of subjects: 0
Study 9686702 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphyllin Retard (theophylline)
Number of subjects: 19
Study 9686702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7912581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver used from the beginning of surgery (group 1)
Number of subjects: 112
Study 7912581 — intervention group
Group type: COMPARATOR
Intervention: No blood conservation techniques (group 2)
Number of subjects: 112
Study 7912581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver used in Redo patients (group 1)
Number of subjects: 112
Study 7912581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver used in CABG patients (group 1)
Number of subjects: 112
Study 7912581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver used in CABG and Redo patients (group 1)
Number of subjects: 112
Study 2532034 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaque fissure sealant
Number of subjects: 0
Study 2532034 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fissure sealant
Number of subjects: 0
Study 31120274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention including a brief, 1-visit intervention on alcohol prevention in pregnancy
Number of subjects: 1236
Study 31120274 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1236
Study 28128983 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-enriched liquid supplement (2 g/day)
Number of subjects: 53
Study 28128983 — intervention group
Group type: COMPARATOR
Intervention: Powdered supplement without EPA
Number of subjects: 53
Study 25882965 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs)
Number of subjects: 93
Study 25882965 — intervention group
Group type: COMPARATOR
Intervention: No regional anesthesia
Number of subjects: 93
Study 23409890 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 23409890 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 0
Study 21680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine shunting
Number of subjects: 98
Study 21680143 — intervention group
Group type: COMPARATOR
Intervention: Selective shunting when collateral perfusion pressure <40 mm Hg
Number of subjects: 98
Study 21680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-filling with normal to <70% contralateral carotid stenosis
Number of subjects: 98
Study 21680143 — intervention group
Group type: COMPARATOR
Intervention: No cross-filling with <70% contralateral carotid stenosis
Number of subjects: 98
Study 21680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-filling with ≥70% contralateral carotid stenosis
Number of subjects: 98
Study 21680143 — intervention group
Group type: COMPARATOR
Intervention: No cross-filling with ≥70% contralateral carotid stenosis
Number of subjects: 98
Study 21680143 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of cross-filling
Number of subjects: 98
Study 18053000 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of exclusive breastfeeding for the first 4-6 months of life according to WHO recommendations
Number of subjects: 1721
Study 18053000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1721
Study 16787192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E‐1 (PGE‐1) treatment
Number of subjects: 123
Study 16787192 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline-buflomedil association (Control)
Number of subjects: 123
Study 15043177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a standard sliding-scale insulin regimen and routine diabetes medications
Number of subjects: 153
Study 15043177 — intervention group
Group type: COMPARATOR
Intervention: Routine diabetes medications (control)
Number of subjects: 153
Study 10890985 — intervention group
Group type: EXPERIMENTAL
Intervention: Medlite II frequency‐doubled Q‐switched Nd:YAG laser
Number of subjects: 27
Study 10890985 — intervention group
Group type: EXPERIMENTAL
Intervention: HGM K1 krypton laser
Number of subjects: 27
Study 10890985 — intervention group
Group type: EXPERIMENTAL
Intervention: DioLite 532‐nm diode‐pumped vanadate laser
Number of subjects: 27
Study 10890985 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 27
Study 9279425 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment involving observation over a nine-week period, with three weeks of treatment focused on lexical development and verb constructions.
Number of subjects: 0
Study 8362313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms/kg
Number of subjects: 60
Study 8362313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms/kg
Number of subjects: 60
Study 8362313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms/kg
Number of subjects: 60
Study 8362313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms/kg
Number of subjects: 60
Study 3536528 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2C
Number of subjects: 42
Study 3536528 — intervention group
Group type: COMPARATOR
Intervention: VMCP (vincristin, melphalan, cyclophosphamide and prednisolone)
Number of subjects: 42
Study 29948858 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) on top of standard therapy for acute heart failure
Number of subjects: 10
Study 29948858 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 10
Study 28359008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion (45°C)
Number of subjects: 42
Study 28359008 — intervention group
Group type: COMPARATOR
Intervention: Icepacks
Number of subjects: 42
Study 28359008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion
Number of subjects: 42
Study 28359008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water immersion and icepacks
Number of subjects: 42
Study 28359008 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up patients
Number of subjects: 42
Study 25888477 — intervention group
Group type: EXPERIMENTAL
Intervention: £100 incentive payment
Number of subjects: 1015
Study 25888477 — intervention group
Group type: COMPARATOR
Intervention: Standard trial invitation letter
Number of subjects: 1015
Study 23696211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling and lavage (barbotage) combined with a US-guided corticosteroid injection in the subacromial bursa (group 1)
Number of subjects: 48
Study 23696211 — intervention group
Group type: COMPARATOR
Intervention: Subacromial corticosteroid injection (SAI) alone (group 2)
Number of subjects: 48
Study 21782095 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 26
Study 18721166 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice per day)
Number of subjects: 50
Study 18721166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17469198 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH), 1 mg every second day for 6 months followed by alternating daily injections of 1 mg and 0.5 mg for another 6 months
Number of subjects: 43
Study 17469198 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH)
Number of subjects: 43
Study 17469198 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study 12617373 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10958866 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ejaculated spermatozoa
Number of subjects: 0
Study 10958866 — intervention group
Group type: COMPARATOR
Intervention: Aged subjects
Number of subjects: 0
Study 8965780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate added to the drug regimen
Number of subjects: 0
Study 8965780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost 50 micrograms p.o. q.i.d.
Number of subjects: 374
Study 1738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost 100 micrograms p.o. q.i.d.
Number of subjects: 374
Study 1738927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 1738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost (both dosages)
Number of subjects: 374
Study 1738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-treated patients
Number of subjects: 374
Study 1738927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not receiving antibody prophylaxis
Number of subjects: 374
Study 6423328 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol 0.5 g/kg body weight
Number of subjects: 40
Study 6423328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 3887375 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-restricted group (0.4-0.6g/kg/BW)
Number of subjects: 199
Study 3887375 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear-facing car safety seat (CSS) for infants <1 year
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear-facing car safety seat (CSS) for toddlers 12-17 months
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-facing car seat with top tether
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-facing car seat using lower anchors
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster seat use for children aged 4-7 years
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle seating position for children 12 years or younger
Number of subjects: 7725
Study 29584489 — intervention group
Group type: EXPERIMENTAL
Intervention: Front seat position for children aged 8-12 years
Number of subjects: 7725
Study 27913032 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone aerosol combined with theophylline tablets
Number of subjects: 44
Study 27913032 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone aerosol combined with placebo tablets
Number of subjects: 44
Study 24837666 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) program
Number of subjects: 1343
Study 24837666 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1343
Study 24837666 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1343
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including radio messages (23.1%), school fliers (20.1%), and friend referral (15%)
Number of subjects: 303
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Team recruitment approach
Number of subjects: 303
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management strategies and make-up sessions
Number of subjects: 303
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Community field trips replacing structured sessions
Number of subjects: 303
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention attendance rates
Number of subjects: 303
Study 21924381 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year and 2-year follow-ups
Number of subjects: 303
Study 20064514 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Number of subjects: 1023
Study 20064514 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Number of subjects: 1023
Study 18324377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic harmonic scalpel (UHS)
Number of subjects: 104
Study 18324377 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (electrocautery and suture ligation)
Number of subjects: 104